



EXPRESS MAIL NO.: EL 477 033 519 US

RECEIVED
MAR 20 2002

TECH CENTER 1600/2900

#25
Amend. C (6/12)
3/22/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Palese et al.

Group Art Unit: 1648

Serial No.: 09/070,629

Examiner: L. Scheiner

Filed: April 30, 1998

Attorney Docket No.: 6923-071-999

For: RECOMBINANT INFLUENZA VIRUSES
EXPRESSING TUMOR-ASSOCIATED
ANTIGENS AS ANTITUMOR AGENTS

AMENDMENT UNDER 37 C.F.R. § 1.116

Box AF
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated September 13, 2001, and in accordance with Rule 116 of the Rules of Practice, please enter the following amendments and consider the following remarks intended to put this application into form for allowance. Applicants submit herewith: (1) Exhibit A, a marked up version of the claims amended herein; (2) Exhibit B, Strobel et al., 2000, *Human Gene Therapy*, 11:2207-2218; (3) an Amendment Fee Transmittal (in duplicate), accompanied by the appropriate provision authorizing payment of the required fee; (4) a Petition For Extension Of Time (in duplicate) for three months up to and including March 13, 2002, accompanied by the appropriate provision authorizing payment of the required fee; (5) a Notice of Appeal from the Primary Examiner to the Board of Patent Appeals and Interferences (in duplicate), accompanied by the appropriate provision authorizing payment of the required fee; (6) a Supplemental Information Disclosure Statement (in duplicate), accompanied by the appropriate provision authorizing payment of

Do
Enrez
4/3/02
(5)